Discontinued — last reported Q3 '23
Equity
Cumulative Gross Losses and Impairments
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ4 2019
Last reportedQ3 2023
How to read this metric
A rising trend indicates persistent underperformance or market-wide stress affecting the firm's long-term holdings.
Detailed definition
This metric aggregates all unrealized losses and impairment charges on investments that have not yet been recognized in...
Peer comparison
Reported in equity or comprehensive income disclosures for firms with significant investment portfolios.
Metric ID:
cumulative_gross_losses_and_impairmentsBusiness Segments
| Segment | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|
| Medical | $2.70B | $3.20B | — | $3.60B | $4.40B | $4.40B | — | $5.30B |
| Pharmaceutical | $829.00M | $829.00M | $829.00M | — | — | — | $829.00M | — |
| Total | — | — | — | — | — | — | — | — |
GMPD, Medical, Other Operating Segment, Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Cumulative Gross Losses and Impairments at Other Companies
Frequently Asked Questions
- What does cumulative gross losses and impairments mean?
- The total amount of value lost on investments that hasn't been officially recorded as a loss on the income statement yet.